Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2019 December;61(4) > Panminerva Medica 2019 December;61(4):464-72

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Panminerva Medica 2019 December;61(4):464-72

DOI: 10.23736/S0031-0808.19.03723-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Chagas disease in Italy: the study’s contribution of Italian researchers

Spinello ANTINORI 1, 2 , Anna L. RIDOLFO 2, Andrea GIACOMELLI 2, Cecilia BONAZZETTI 1, 2, Mario CORBELLINO 2, Massimo GALLI 1, 2

1 Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; 2 III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy



Chagas disease (CD) is an emerging infection in Italy as the consequence of the huge immigration from Latin American countries observed during the last ten-fifteen years. However, the interest of Italian researchers on CD dates back to the ’80-90s of the last century with studies conducted in collaboration with Brazilian and Argentinian colleagues by Italian cardiologists and pathologists. Moreover, the first demonstration of the existence in the pre-Columbian America of Chagas disease in a Peruvian mummy was made by a group of Italian paleopathologists. Seroprevalence studies performed between 2010-2014 in Negrar (Verona), Bergamo, Milan, Florence and Rome shows Trypanosoma cruzi infection ranging from 3.9% to 17.1% with people coming from Bolivia as the most affected. As observed in Latin America about 30% of screened subjects in Italy are affected by cardiac or digestive forms of CD. More than 20% of subjects treated with benznidazole discontinued it permanently due to adverse events.


KEY WORDS: Chagas disease; Italy; Prevalence; Trypanosoma cruzi

top of page